Corline Biomedical AB (SE:CLBIO)
:CLBIO
Want to see SE:CLBIO full AI Analyst Report?
CLBIO Stock Chart & Stats
kr16.40
-kr0.06(-0.63%)
At close: 4:00 PM EST
kr16.40
-kr0.06(-0.63%)
Day’s Range― - ―
52-Week Rangekr9.52 - kr27.20
Previous CloseN/A
Volume1.95K
Average Volume (3M)90.01K
Market Cap
kr473.01M
Enterprise Valuekr459.71M
Total Cash (Recent Filing)kr32.90M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding26,133,118
10 Day Avg. Volume161,073
30 Day Avg. Volume90,008
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)4.33
Price to Sales (P/S)53.02
P/FCF Ratio-22.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)kr44.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt materially reduces financial risk and interest burden, extending runway for a cash-burning biotech. With no leverage, management has greater strategic optionality—pivoting R&D, partnerships, or commercialization—without near-term covenant pressure that can impede long-term product development.
Revenue Rebound (TTM +29.2%)A 29.2% TTM revenue rebound signals improving commercial traction for the company’s heparin-based surface technologies. Durable top-line recovery supports scaling opportunities, better unit economics long-term, and the potential to convert R&D into repeatable sales across medical-device channels.
Strong Equity Base Vs AssetsA large equity cushion relative to assets provides capital stability and reduces dilution risk from immediate fundraising. This strong capital base supports multi-period R&D and commercialization efforts, allowing the firm to pursue clinical partnerships or device integrations without urgent capital raises.
Bears Say
Negative Gross Profit And Large Operating LossesPersistent negative gross profit and ~-14M EBIT indicate core unit economics and cost structure are not yet sustainable. Over several quarters this undermines scalability: until gross margins improve, expansion increases losses and delays path to durable profitability despite revenue growth.
Material Cash Burn And Weak Cash GenerationDeeply negative operating and free cash flow reflects ongoing cash consumption to fund operations and R&D. This raises reliance on the equity base or financing; sustaining operations through product commercialization or regulatory steps will require capital, potentially diluting shareholders or constraining strategy.
Volatile And Unstable ProfitabilityEarnings volatility across recent years suggests inconsistent demand or lumpy commercialization progress. Structural instability in profitability complicates forecasting, weakens investor confidence, and means management must prove sustained margin recovery before the business demonstrates predictable, long-term cash generation.
CLBIO FAQ
What was Corline Biomedical AB’s price range in the past 12 months?
Corline Biomedical AB lowest stock price was kr9.52 and its highest was kr27.20 in the past 12 months.
What is Corline Biomedical AB’s market cap?
Corline Biomedical AB’s market cap is kr473.01M.
When is Corline Biomedical AB’s upcoming earnings report date?
Corline Biomedical AB’s upcoming earnings report date is Aug 21, 2026 which is in 68 days.
How were Corline Biomedical AB’s earnings last quarter?
Corline Biomedical AB released its earnings results on May 08, 2026. The company reported -kr0.098 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.098.
Is Corline Biomedical AB overvalued?
According to Wall Street analysts Corline Biomedical AB’s price is currently Overvalued.
Does Corline Biomedical AB pay dividends?
Corline Biomedical AB does not currently pay dividends.
What is Corline Biomedical AB’s EPS estimate?
Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Corline Biomedical AB have?
Corline Biomedical AB has 26,133,118 shares outstanding.
What happened to Corline Biomedical AB’s price movement after its last earnings report?
Corline Biomedical AB reported an EPS of -kr0.098 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.179%.
Which hedge fund is a major shareholder of Corline Biomedical AB?
Currently, no hedge funds are holding shares in SE:CLBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Corline Biomedical AB
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.